File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1159/000446819
- Scopus: eid_2-s2.0-84978058374
- WOS: WOS:000384871500005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
Title | Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response |
---|---|
Authors | |
Keywords | Age-related macular degeneration |
Issue Date | 2016 |
Citation | Ophthalmologica, 2016, v. 236 n. 2, p. 88-94 How to Cite? |
Abstract | © 2016 S. Karger AG, BaselObjective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of ≥15 letters at the 6-month endpoint after adjusting for potential confounders. Results:CFH haplotypes were associated with a gain of ≥15 letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of ≥15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion:CFH is implicated in nAMD patient treatment response to ranibizumab. |
Persistent Identifier | http://hdl.handle.net/10722/228255 |
ISSN | 2023 Impact Factor: 2.1 2023 SCImago Journal Rankings: 0.992 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chaudhary, Varun | - |
dc.contributor.author | Brent, Michael | - |
dc.contributor.author | Lam, Wai Ching | - |
dc.contributor.author | Devenyi, Robert | - |
dc.contributor.author | Teichman, Joshua | - |
dc.contributor.author | Mak, Michael | - |
dc.contributor.author | Barbosa, Joshua | - |
dc.contributor.author | Kaur, Harneel | - |
dc.contributor.author | Carter, Ronald | - |
dc.contributor.author | Farrokhyar, Forough | - |
dc.date.accessioned | 2016-08-01T06:45:35Z | - |
dc.date.available | 2016-08-01T06:45:35Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Ophthalmologica, 2016, v. 236 n. 2, p. 88-94 | - |
dc.identifier.issn | 0030-3755 | - |
dc.identifier.uri | http://hdl.handle.net/10722/228255 | - |
dc.description.abstract | © 2016 S. Karger AG, BaselObjective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of ≥15 letters at the 6-month endpoint after adjusting for potential confounders. Results:CFH haplotypes were associated with a gain of ≥15 letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of ≥15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion:CFH is implicated in nAMD patient treatment response to ranibizumab. | - |
dc.language | eng | - |
dc.relation.ispartof | Ophthalmologica | - |
dc.subject | Age-related macular degeneration | - |
dc.title | Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1159/000446819 | - |
dc.identifier.scopus | eid_2-s2.0-84978058374 | - |
dc.identifier.hkuros | 272451 | - |
dc.identifier.volume | 236 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 88 | - |
dc.identifier.epage | 94 | - |
dc.identifier.eissn | 1423-0267 | - |
dc.identifier.isi | WOS:000384871500005 | - |
dc.identifier.issnl | 0030-3755 | - |